Nano Diagnostic Chains

Aspira Pathlab & Diagnostics Ltd.

ASPIRA

Market Cap
₹126 Cr.
P/E
52.56

Aspira Pathlab & Diagnostics Ltd.

  • Aspira Pathlab&Diagn
  • Nephro Care India
  • Invicta Diagnostic

FAQs on Aspira Pathlab & Diagnostics Ltd. Shareprice

Aspira Pathlab&Diagn has given better returns compared to its competitors.
Aspira Pathlab&Diagn has grown at ~149.83% over the last 1yrs while peers have grown at a median rate of 8.85%

Yes, Aspira Pathlab&Diagn is expensive.
Latest PE of Aspira Pathlab&Diagn is 2551, while 3 year average PE is 29.96.
Also latest EV/EBITDA of Aspira Pathlab&Diagn is 89.86 while 3yr average is 24.33.

View FAQ's On Business

Growth Table

  • Aspira Pathlab & Diagnostics Ltd.
  • Nephro Care India
  • Invicta Diagnostic

Balance Sheet

  • Aspira Pathlab & Diagnostics Ltd.
  • Nephro Care India
  • Invicta Diagnostic

Balance Sheet Snapshot

No data available.

Fund Flow Analysis

  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.
*Data is as of latest FY end

Profit & Loss

  • Aspira Pathlab & Diagnostics Ltd.
  • Nephro Care India
  • Invicta Diagnostic

Cash Flow

  • Aspira Pathlab & Diagnostics Ltd.
  • Nephro Care India
  • Invicta Diagnostic

Cash Flow Analysis

  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.

Ratios

= Dominant Factor
  • Aspira Pathlab & Diagnostics Ltd.
  • Nephro Care India
  • Invicta Diagnostic

Quarterly Results

  • Aspira Pathlab & Diagnostics Ltd.
  • Nephro Care India
  • Invicta Diagnostic

Reverse DCF

locked
Cr
locked
5 YEAR
locked 5
10 YEAR
locked 10
20 YEAR
locked 20
Implied Growth Rate over a 5 year period*
Implied Growth Rate over a 10 year period*
Implied Growth Rate over a 20 year period*
*Implied Growth calculated using Newton-Raphson method.
Learn how to use Reverse DCF

FAQs on Aspira Pathlab & Diagnostics Ltd. Financials

Balance sheet of Aspira Pathlab&Diagn is strong.
It shouldn't have solvency or liquidity issues.

The net debt of Aspira Pathlab&Diagn is decreasing.
Latest net debt of Aspira Pathlab&Diagn is -₹2.96 Crs as of Mar-25.
This is less than Mar-24 when it was -₹1.66 Crs.

The profit is oscillating.
The profit of Aspira Pathlab&Diagn is ₹2.02 Crs for Mar 2025, -₹2.67 Crs for Mar 2024 and -₹0.09 Crs for Mar 2023

The company seems to be paying a very low dividend.
Investors need to see where the company is allocating its profits.
Aspira Pathlab&Diagn latest dividend payout ratio is 0% and 3yr average dividend payout ratio is 0%

Companies resources are majorly tied in miscellaneous assets

View FAQ's On Shareholding
Ideas Dashboard
Results
Timeline
Watchlist
Portfolio
Alerts
Stock Screener
Market
Raw Material
Data feed provided by Accord Fintech